Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1666 to 1680 of 7682 results

  1. Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]

    In development [GID-TA10248] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Shared decision-making: practical guidance for health and social care professionals

    Awaiting development [GID-QS10097] Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

    In development [GID-TA10542] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Gosuranemab for treating progressive supranuclear palsy [ID1607]

    Awaiting development [GID-TA10553] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

    In development [GID-TA10607] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

    In development [GID-TA10573] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

    In development [GID-TA10623] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

    Awaiting development [GID-TA10604] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]

    In development [GID-TA10250] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development [GID-TA10664] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

    Awaiting development [GID-TA10684] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

    Awaiting development [GID-TA10685] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

    Awaiting development [GID-TA10662] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Sotagliflozin for treating type 2 diabetes [ID1657]

    Awaiting development [GID-TA10665] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. eXroid for internal haemorrhoids

      Status ...

    Medical technologies guidance
    Topic selection